Paid Clinical Trials in Oregon

Oregon has 1,203 paid clinical trials enrolling now across cities including Portland, Eugene and Newberg. Search by condition, age, or phase to find compensated research studies accepting participants near you.

Both patients and healthy volunteers may qualify. Most studies offer compensation for time and travel.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: July 31, 2026.

Filter results

State

City

Recruitment status

Phase

Study type

Intervention

Condition

Sex

Age

Healthy volunteers only

1,071 clinical trials

Phase III Study to Assess the Safety and Efficacy of SL1002 for Osteoarthritis Knee Pain

for Osteoarthritis Knee Pain

Sites in Eugene +20 more locations

Sponsor: Saol Therapeutics Inc

Sex: All·Age: 40+

Code: NCT07226258·Phase 3·Recruiting·Listed Nov 2025

Apply to this trial

A Study to Evaluate the Efficacy and Safety of Cannabidiol Oral Solution (CBD-OS [GWP42003-P, JZP926]) for the Treatment of Focal-Onset Seizures

for Focal Seizures

Sites in Portland +23 more locations

Sponsor: Jazz Pharmaceuticals

Sex: All·Age: 12 - 75

Code: NCT07233239·Phase 1·Recruiting·Listed Nov 2025

Apply to this trial

A Study to Investigate Mibavademab in Adult Women With Functional Hypothalamic Amenorrhea

for Functional Hypothalamic Amenorrhea (FHA)

Sites in Portland +9 more locations

Sponsor: Regeneron Pharmaceuticals

Sex: Female·Age: 18 - 40

Code: NCT07235917·Phase 2·Recruiting·Listed Nov 2025

Apply to this trial

A Study Exploring Changes in a Variety of Biomarkers Following Dosing With MT1988 in Participants at Clinical High Risk for Psychosis

for Clinical High Risk for Psychosis (CHR)

Sites in Eugene +14 more locations

Sponsor: Monument Therapeutics Limited

Sex: All·Age: 17 - 30

Code: NCT07226895·Phase 1, Phase 2·Recruiting·Listed Nov 2025

Apply to this trial

A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)

for Squamous Non-small Cell Lung Cancer

Drug: Intismeran autogene

Sites in Corvallis +9 more locations

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT07221474·Phase 2·Recruiting·Listed Oct 2025

Apply to this trial

A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)

for Cervical Cancer

Sites in Eugene +18 more locations

Sponsor: Merck Sharp & Dohme LLC

Sex: Female·Age: 18+

Code: NCT07216703·Phase 3·Recruiting·Listed Oct 2025

Apply to this trial

A Safety and Efficacy Study of a One-time Intravitreal Injection of SAR446597 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration

for Geographic Atrophy

Sites in Eugene +14 more locations

Sponsor: Sanofi

Sex: All·Age: 60+

Code: NCT07215234·Phase 1, Phase 2·Recruiting·Listed Oct 2025

Apply to this trial

A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors

for Advanced or Metastatic Solid Tumors

Sites in Portland +14 more locations

Sponsor: Takeda

Sex: All·Age: 18+

Code: NCT07205718·Phase 1, Phase 2·Recruiting·Listed Oct 2025

Apply to this trial

A Study of the Efficacy and Safety of Danicamtiv in Participants With Symptomatic Genetic and Familial Dilated Cardiomyopathy

for Symptomatic Genetic Dilated Cardiomyopathy

Sites in Portland +22 more locations

Sponsor: Kardigan, Inc.

Sex: All·Age: 18+

Code: NCT07210723·Phase 2, Phase 3·Recruiting·Listed Oct 2025

Apply to this trial

A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)

for Non-small Cell Lung Cancer

Drug: Calderasib

Sites in Bend +8 more locations

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT07190248·Phase 3·Recruiting·Listed Sep 2025

Apply to this trial

A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer

for Nausea

Sites in Medford +19 more locations

Sponsor: Eli Lilly and Company

Sex: All·Age: 18+

Code: NCT07169851·Phase 2·Recruiting·Listed Sep 2025

Apply to this trial

IGNITE: Study of Tirabrutinib vs Rituximab/Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)

for Relapsed/Refractory Primary Central Nervous System Lymphoma

Drug: Rituximab

Sites in Portland +21 more locations

Sponsor: Ono Pharmaceutical Co., Ltd.

Sex: All·Age: 18+

Code: NCT07104032·Phase 3·Recruiting·Listed Aug 2025

Apply to this trial

A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease

for Colorectal Cancer

Sites in Portland +21 more locations

Sponsor: AbbVie

Sex: All·Age: 18+

Code: NCT07023289·Phase 2·Recruiting·Listed Jun 2025

Apply to this trial

A Study of Zasocitinib in Adults With Hidradenitis Suppurativa

for Hidradenitis Suppurativa

Drug: Zasocitinib

Sites in Portland +14 more locations

Sponsor: Takeda

Sex: All·Age: 18+

Code: NCT07244263·Phase 2·Recruiting·Listed Nov 2025

Apply to this trial

A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

for Multiple Myeloma

Drug: Daratumumab

Sites in Eugene +16 more locations

Sponsor: AbbVie

Sex: All·Age: 18+

Code: NCT07095452·Phase 2, Phase 3·Recruiting·Listed Jul 2025

Apply to this trial

A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

for Metastatic Gastric Adenocarcinoma

Sites in Salem +18 more locations

Sponsor: BeOne Medicines

Sex: All·Age: 18+

Code: NCT07043400·Phase 3·Recruiting·Listed Jun 2025

Apply to this trial

Phase 4 Study: Long-term Safety and Efficacy of NT-501 in MacTel Type 2, Including Sham Procedure Participants

for Macular Telangiectasia Type 2 (MacTel)

Sites in Portland +22 more locations

Sponsor: Neurotech Pharmaceuticals

Sex: All·Age: 18+

Code: NCT06971939·Phase 4·Recruiting·Listed May 2025

Apply to this trial

The Use of p48/64 MW HPC Flow Modulation Device in the Treatment of Wide-necked Intracranial Aneurysms

for Hemorrhagic Stroke

Sites in Portland +20 more locations

Sponsor: phenox Inc.

Sex: All·Age: 18+

Code: NCT07143019·Recruiting·Listed Aug 2025

Apply to this trial

A Real-world Chronic Myelogenous Leukemia (CML) Patient Disease Registry to Describe Patient Experience and Clinical Outcomes Among Patients With CML Receiving Approved First or Second Line Tyrosine Kinase Inhibitor (TKI) Therapy

for Chronic Myelogenous Leukemia - Chronic Phase

Sites in Salem +16 more locations

Sponsor: Novartis Pharmaceuticals

Sex: All·Age: 18 - 100

Code: NCT07091019·Recruiting·Listed Jul 2025

Apply to this trial

A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease

for Alzheimer's Disease

Sites in Portland +23 more locations

Sponsor: Novartis Pharmaceuticals

Sex: All·Age: 50 - 85

Code: NCT07094516·Phase 2·Recruiting·Listed Jul 2025

Apply to this trial

The Lilac Device Trial - IMPACT: A Clinical Investigation on IMproving Peripheral Neuropathy Induced by Chemotherapy With Advanced Compression Technology - A Safety and Efficacy Study

for Chemotherapy Induced Peripheral Neuropathy (CIPN)

Sites in Portland +15 more locations

Sponsor: Luminate Medical, Inc.

Sex: All·Age: 18+

Code: NCT07142304·Recruiting·Listed Aug 2025

Apply to this trial

Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer

for Gastric Cancer

Sites in Portland +14 more locations

Sponsor: Daiichi Sankyo

Sex: All·Age: 18+

Code: NCT06731478·Phase 3·Recruiting·Listed Dec 2024

Apply to this trial

A Study to Test Whether BI 1815368 Helps People With an Eye Condition Called Diabetic Macular Edema

for Macular Edema

Sites in Eugene +22 more locations

Sponsor: Boehringer Ingelheim

Sex: All·Age: 18+

Code: NCT06962839·Phase 2·Recruiting·Listed May 2025

Apply to this trial

Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer

for Non-small Cell Lung Cancer

Sites in Bend +24 more locations

Sponsor: Daiichi Sankyo

Sex: All·Age: 18+

Code: NCT06899126·Phase 3·Recruiting·Listed Mar 2025

Apply to this trial

A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH) (ROCSTAR STUDY)

for Pulmonary Arterial Hypertension (PAH)

Sites in Bend +9 more locations

Sponsor: AllRock Bio, Inc.

Sex: All·Age: 18+

Code: NCT07175038·Phase 2·Recruiting·Listed Sep 2025

Apply to this trial

Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors

for Small Cell Lung Cancer Metastatic or Locally Advanced

Sites in Portland +19 more locations

Sponsor: SystImmune Inc.

Sex: All·Age: 18+

Code: NCT07080242·Phase 1·Recruiting·Listed Jul 2025

Apply to this trial

A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer

for Non-Muscle Invasive Bladder Neoplasms

Sites in Springfield +21 more locations

Sponsor: Janssen Research & Development, LLC

Sex: All·Age: 18+

Code: NCT06919965·Phase 3·Recruiting·Listed Apr 2025

Apply to this trial

A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)

for Advanced Liver Cancers

Sites in Portland +13 more locations

Sponsor: Hoffmann-La Roche

Sex: All·Age: 18+

Code: NCT04524871·Phase 1, Phase 2·Recruiting·Listed Aug 2020

Apply to this trial

A Study of EP0031 (Lunbotinib) in Patients With Advanced RET-altered Malignancies

for NSCLC

Drug: EP0031

Sites in Portland +14 more locations

Sponsor: Ellipses Pharma

Sex: All·Age: 18+

Code: NCT05443126·Phase 1, Phase 2·Recruiting·Listed Jul 2022

Apply to this trial

An Open-Label ProSpective MultiCENTer Study to Evaluate Safety and Tolerability of Dry Powder Inhaled Treprostinil in PH

for Pulmonary Hypertension

Sites in Bend +7 more locations

Sponsor: Liquidia Technologies, Inc.

Sex: All·Age: 18 - 80

Code: NCT06129240·Recruiting·Listed Nov 2023

Apply to this trial

A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors

for CLL

Sites in Eugene +21 more locations

Sponsor: BeOne Medicines

Sex: All·Age: 18+

Code: NCT06846671·Phase 3·Recruiting·Listed Feb 2025

Apply to this trial

Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)

for Non-small Cell Lung Cancer (NSCLC)

Sites in Corvallis +9 more locations

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT06170788·Phase 3·Recruiting·Listed Dec 2023

Apply to this trial

A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)

for Urinary Bladder Neoplasms

Drug: Intismeran autogene

Sites in Portland +18 more locations

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT06833073·Phase 2·Recruiting·Listed Feb 2025

Apply to this trial

A Study to Test Whether Spesolimab Helps People With a Skin Condition Called Pyoderma Gangrenosum

for Pyoderma Gangrenosum

Sites in Portland +22 more locations

Sponsor: Boehringer Ingelheim

Sex: All·Age: 18+

Code: NCT06624670·Phase 3·Recruiting·Listed Oct 2024

Apply to this trial

Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

for Endometrial Cancer

Sites in Portland +16 more locations

Sponsor: SystImmune Inc.

Sex: All·Age: 18+

Code: NCT06293898·Phase 1·Recruiting·Listed Mar 2024

Apply to this trial

A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors

for Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Drug: Cemiplimab

Sites in Portland +22 more locations

Sponsor: Regeneron Pharmaceuticals

Sex: All·Age: 18+

Code: NCT03972657·Phase 1, Phase 2·Recruiting·Listed Jun 2019

Apply to this trial

A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)

for Malignant Neoplasm

Sites in Portland +16 more locations

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 1 Month - 17

Code: NCT06941272·Phase 1, Phase 2·Recruiting·Listed Apr 2025

Apply to this trial

A Study of JNT-517 in Participants With Phenylketonuria (PKU)

for Phenylketonuria

Sites in Portland +9 more locations

Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.

Sex: All·Age: 18+

Code: NCT06971731·Phase 3·Recruiting·Listed May 2025

Apply to this trial

A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)

for Non-Small Cell Lung Cancer

Drug: Cemiplimab

Sites in Portland +14 more locations

Sponsor: Regeneron Pharmaceuticals

Sex: All·Age: 18+

Code: NCT06465329·Phase 2·Recruiting·Listed Jun 2024

Apply to this trial

A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)

for Carcinoma, Non-Small-Cell Lung

Sites in Portland +17 more locations

Sponsor: Johnson & Johnson Enterprise Innovation Inc.

Sex: All·Age: 18+

Code: NCT06667908·Phase 2·Recruiting·Listed Oct 2024

Apply to this trial